ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • adipose tissue and sarcopenia
  • adipose tissue and total cholesterol
  • Adiposity
  • adjuvant arthritis
  • adjuvant arthritis and osteoclasts
  • Administrative Data
  • administrative databases
  • administrative databases and epidemiologic methods
  • administrative databases and evaluation
  • Administrative databases and gout
  • administrative databases and health care use
  • administrative databases and pediatric rheumatology
  • administrative databases and prognostic factors
  • administrative databases and rheumatoid arthritis
  • Administrative databases and rheumatoid arthritis (RA)
  • administrative databases and spondylarthritis
  • administrative databases and systemic lupus erythematosus (SLE)
  • administrative databases and Validity
  • administrative databases and vasculitis
  • Adolescence
  • Adolescence and Transition
  • Adolescent
  • adolescent development
  • Adolescent patients
  • adolescent patients and pediatric rheumatology
  • adolescent patients and quality improvement
  • adolescent patients and social media
  • adolescent patients and Transition
  • Adrenal insufficiency
  • ADSC and monocytes
  • adult onset ankylosing spondylitis (AoAS) and late onset ankylosing spondylitis (LoAS)
  • Adult-onset Still's disease
  • adult-onset Still's disease and apoptosis
  • adult-onset Still's disease and canakinumab
  • adult-onset Still's disease and chemokines
  • adult-onset Still's disease and familial Mediterranean fever
  • adult-onset Still's disease and interleukins (IL)
  • adult-onset Still's disease and macrophage activation syndrome
  • Adult-onset Still's disease and malignancy
  • adult-onset Still's disease and natural killer (NK) cells
  • Adult-onset Still's disease and tocilizumab
  • adults
  • advance care planning
  • Advanced glycation end-products (AGEs)
  • Advanced glycation end-products (AGEs) and systemic sclerosis
  • Adverse events
  • Adverse events and anti-TNF therapy
  • adverse events and arthritis
  • adverse events and autoimmune diseases
  • adverse events and azathioprine
  • adverse events and big data
  • adverse events and cancer treatments
  • adverse events and cohort
  • adverse events and combination therapies
  • adverse events and data analysis
  • adverse events and exercise
  • adverse events and Gene Expression
  • adverse events and gout
  • adverse events and heart disease
  • adverse events and infection
  • adverse events and meta-analysis
  • adverse events and osteoarthritis
  • adverse events and polymyalgia rheumatica
  • adverse events and rheumatic disease
  • adverse events and rheumatoid arthritis
  • adverse events and rheumatoid arthritis (RA)
  • Adverse events and systemic lupus erythematosus (SLE)
  • adverse events and vasculitis
  • Advocacy
  • Advocacy and cardiovascular disease
  • Aerobic
  • aerobic exercise and tai chi
  • affinity maturation
  • Africa and classification criteria
  • African American and predictive factors
  • African Ancestry
  • African-Americans
  • African-Americans and human leukocyte antigens (HLA)
  • African-Americans and metabolomics
  • African-Americans and monocytes
  • African-Americans and proteinuria
  • African-Americans and rheumatoid arthritis (RA)
  • African-Americans and self-management
  • African-Americans and systemic lupus erythematosus (SLE)
  • African-Americans and systemic sclerosis
  • African-Americans and total joint replacement
  • African-Americans and vasculitis
  • agapss and thrombosis
  • Age Associated/Autoimmune B cells
  • Age of diagnosis
  • age-associated B cells and Cholesterol Homeostasis
  • Aggrecanase
  • Aging
  • Aging and animal models
  • Aging and autophagy
  • Aging and drug treatment
  • Aging and familial Mediterranean fever
  • Aging and shoulder disorders
  • Air pollution
  • alcohol
  • alcohol use
  • Alcohol use and gout
  • alcohol use and pain
  • alcohol use and tophaceous gout
  • alendronate and fractures
  • algorithm
  • Alignment
  • Alignment and osteoarthritis
  • alkaline phosphatase
  • Allopurinol
  • allopurinol and cardiovascular disease
  • allopurinol and colchicine
  • allopurinol and EHR
  • allopurinol and genetics
  • Allopurinol and gout
  • allopurinol and gout flare
  • allopurinol and primary care
  • Allopurinol and uric acid
  • alternative
  • Alternative Activation
  • alternative medicine
  • alternative medicine and patient outcomes
  • alveolitis
  • American College of Rheumatology Criteria
  • amino acid and plasmablast differentiation
  • Amyloidosis
  • Amyloidosis and ankylosing spondylitis (AS)
  • amyloidosis and familial Mediterranean fever
  • Amyloidosis and positron emission tomography (PET)
  • Amyopathic dermatomyositis
  • amyopathic dermatomyositis and interstitial lung disease
  • ANA
  • ANA and antibodies
  • ANA and Diagnostic Tests
  • ANA and education
  • ANA and ENA
  • ANA and environmental factors
  • ANA and health care cost
  • ANA and laboratory tests
  • ANA and quality improvement
  • ANA and rheumatic disease
  • ANA and SLE
  • ANA and systemic illness
  • ANA and systemic lupus erythematosus (SLE)
  • Anakinra
  • anakinra and AA-amyloidosis
  • anakinra and Biologic agents
  • anakinra and bone disease
  • Anakinra and cardiovascular disease
  • anakinra and clinical practice
  • anakinra and familial Mediterranean fever
  • anakinra and fever
  • Anakinra and gout
  • anakinra and histopathologic
  • anakinra and interleukins (IL)
  • anakinra and recurrent pericarditis
  • anakinra and treatment
  • analgesics
  • analgesics and Chronic pain
  • analgesics and drug therapy
  • Anatomy
  • Anatomy and arthritis
  • Anatomy and education
  • Anatomy and educational innovation
  • ANCA
  • ANCA and asthma
  • ANCA and body mass
  • ANCA and C-reactive protein (CRP)
  • ANCA and cardiovascular disease
  • ANCA and CD T cells
  • ANCA and Churg-Strauss syndrome
  • ANCA and Clinical Response
  • ANCA and Elderly
  • ANCA and genetics
  • ANCA and histopathologic
  • ANCA and rituximab
  • ANCA and systemic lupus erythematosus (SLE)
  • ANCA and systemic sclerosis
  • ANCA and systemic vasculitides
  • ANCA and vasculitis
  • ANCA and Wegener's granulomatosis
  • ANCA associated vasculitis
  • and autoantibodies
  • and cardiovascular disease
  • and DMARDs
  • and drug off
  • and fatigue
  • and Lung Disease
  • and quality of life
  • and Rheumatoid Factor
  • and SLE
  • and Systemic Inflammatory
  • and women's health
  • Anemia
  • anemia and epidemiologic methods
  • Anemia and gout
  • anemia and systemic lupus erythematosus (SLE)
  • angiitis
  • angioedema and pediatric rheumatology
  • Angiogenesis
  • « Previous Page
  • 1
  • [2]
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology